DermTech Inc. (NASDAQ: DMTK) is 14.06% higher on its value in year-to-date trading and has touched a low of $8.69 and a high of $40.66 in the current 52-week trading range. The DMTK stock was last observed hovering at around $33.58 in the last trading session, with the day’s gains setting it 3.42% off its average median price target of $23.50 for the next 12 months. It is also -8.82% off the consensus price target high of $34.00 offered by 5 analysts, but current levels are -85.0% lower than the price target low of $20.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $37.00, the stock is 49.46% and 111.26% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.38 million and changing 10.18% at the moment leaves the stock 173.24% off its SMA200. DMTK registered 296.57% gain for a year compared to 6-month gain of 224.28%. The firm has a 50-day simple moving average (SMA 50) of $19.74 and a 200-day simple moving average (SMA200) of $13.84.
The stock witnessed a 223.14% loss in the last 1 month and extending the period to 3 months gives it a 211.45%, and is 15.73% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 15.25% over the week and 15.43% over the month.
DermTech Inc. (DMTK) has around 60 employees, a market worth around $804.01M and $5.40M in sales. Distance from 52-week low is 325.78% and -9.00% from its 52-week high. The company has generated returns on investments over the last 12 months (-133.40%).
DermTech Inc. (DMTK) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for DermTech Inc. (DMTK) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
DermTech Inc. quarterly earnings per share for the current quarter are estimated at -$0.57 with sales reaching $1.62M over the same period.The EPS is expected to grow by 17.10% this year, but quarterly earnings will post 287.00% year-over-year.
DermTech Inc. (DMTK) Top Institutional Holders
75 institutions hold shares in DermTech Inc. (DMTK), with 4.62M shares held by insiders accounting for 23.57% while institutional investors hold 75.43% of the company’s shares. The shares outstanding are 18.93M, and float is at 9.26M with Short Float at 10.31%. Institutions hold 57.65% of the Float.
The top institutional shareholder in the company is RTW Investments LP with over 2.89 million shares valued at $34.5 million. The investor’s holdings represent 14.73% of the DMTK Shares outstanding. As of Sep 29, 2020, the second largest holder is Casdin Capital, LLC with 1.43 million shares valued at $17.07 million to account for 7.29% of the shares outstanding. The other top investors are Farallon Capital Management LLC which holds 1.22 million shares representing 6.23% and valued at over $14.58 million, while Federated Hermes, Inc. holds 6.20% of the shares totaling 1.21 million with a market value of $14.52 million.
DermTech Inc. (DMTK) Insider Activity
The most recent transaction is an insider purchase by RTW INVESTMENTS, LP, the company’s 10% Owner. SEC filings show that RTW INVESTMENTS, LP bought 200,000 shares of the company’s common stock on Jan 07 at a price of $29.50 per share for a total of $5.9 million. Following the purchase, the insider now owns 3.09 million shares.
DermTech Inc. disclosed in a document filed with the SEC on Dec 14 that PANCOAST SCOTT R (Director) sold a total of 6,000 shares of the company’s common stock. The trade occurred on Dec 14 and was made at $13.93 per share for $83569.0. Following the transaction, the insider now directly holds 44132.0 shares of the DMTK stock.
Still, SEC filings show that on Dec 14, Jansen Burkhard (Chief Medical Officer) disposed off 5,000 shares at an average price of $12.41 for $62050.0. The insider now directly holds 79,037 shares of DermTech Inc. (DMTK).